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Abstract
Microsatellite instability promotes colonic tumorigenesis through generating frameshift mutations at coding microsatellites
of tumor suppressor genes, such as TGFBR2 and ACVR2. As a consequence, signaling through these TGFb family receptors is
abrogated in DNA Mismatch repair (MMR)-deficient tumors. How these mutations occur in real time and mutational rates of
these human coding sequences have not previously been studied. We utilized cell lines with different MMR deficiencies
(hMLH1
2/2, hMSH6
2/2, hMSH3
2/2, and MMR-proficient) to determine mutation rates. Plasmids were constructed in which
exon 3 of TGFBR2 and exon 10 of ACVR2 were cloned +1 bp out of frame, immediately after the translation initiation codon
of an enhanced GFP (EGFP) gene, allowing a 21 bp frameshift mutation to drive EGFP expression. Mutation-resistant
plasmids were constructed by interrupting the coding microsatellite sequences, preventing frameshift mutation. Stable cell
lines were established containing portions of TGFBR2 and ACVR2, and nonfluorescent cells were sorted, cultured for 7–35
days, and harvested for flow cytometric mutation detection and DNA sequencing at specific time points. DNA sequencing
revealed a 21 bp frameshift mutation (A9 in TGFBR2 and A7 in ACVR2) in the fluorescent cells. Two distinct fluorescent
populations, M1 (dim, representing heteroduplexes) and M2 (bright, representing full mutants) were identified, with the M2
fraction accumulating over time. hMLH1 deficiency revealed 11 (5.91610
24) and 15 (2.18610
24) times higher mutation rates
for the TGFBR2 and ACVR2 microsatellites compared to hMSH6 deficiency, respectively. The mutation rate of the TGFBR2
microsatellite was ,3 times higher in both hMLH1 and hMSH6 deficiencies than the ACVR2 microsatellite. The 21b p
frameshift mutation rates of TGFBR2 and ACVR2 microsatellite sequences are dependent upon the human MMR background.
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Introduction
The DNA MMR system consists of proteins that act in concert
to recognize and coordinate repair of nucleotide base mismatches
and slippage mistakes at microsatellite sequences on newly
synthesized DNA [1]. In humans, MMR activity requires the
proper functioning of hMutSa and hMutSb to recognize defects,
and hMutLa to coordinate repair. hMutSa (heterodimer of
hMSH2 and hMSH6) recognizes single nucleotide interstrand
mispairs and insertion/deletion loops (IDLs) containing 1 or 2
looped nucleotides, whereas hMutSb (heterodimer of hMSH2 and
hMSH3) recognizes IDLs containing 2 or more looped nucleotides
that occur at microsatellite sequences [2]. The hMutS complexes
interact with the hMutLa protein complex (heterodimer of
hMLH1 and hPMS2) to coordinate excision and repair of the
mispair or IDL [3–5]. Loss of any of the components of the MMR
system inactivates or attenuates DNA repair, and is the cause of
microsatellite instability (MSI) [6,7]. Patients with germline
mutations of hMSH2, hMLH1, hMSH6,o rhPMS2 have Lynch
syndrome (formerly known as hereditary nonpolyposis colon
cancer or HNPCC), the most common familial form of colorectal
cancer [8–11]. Epigenetic inactivation of hMLH1 through
promoter hypermethylation occurs in 15–20% of sporadic
colorectal cancers [12,13]. In either instance, the resulting
colorectal cancers display the phenotype of MSI observed as
novel length mutations at microsatellites [7].
Microsatellites are nucleotide repeat sequences that are
ubiquitous throughout the genome [14]. Rarely but significantly,
microsatellites are present in the coding regions (exons) of critical
growth regulatory genes and are targeted for frameshift mutation
when DNA MMR is defective [15]. These frameshift mutations,
which occur due to non-repair of exonic IDL, are thought to drive
the pathogenesis of colorectal cancers and other MSI tumors. The
type II receptor for transforming growth factor b (TGFBR2) has an
A10 microsatellite within exon 3. Frameshift mutation of this
polyadenine sequence truncates TGFBR2, making it nonfunctional
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MSI, TGFBR2 is frameshift mutated at both alleles [17]. This
mutation allows the tumor to escape the growth suppressive effects
of TGFb–SMAD signaling. TGFBR2 mutation appears to be a late
event in MSI adenomas and tightly correlated with progression of
these adenomas to malignant carcinomas [18].
The activin type II receptor, ACVR2, contains polyadenine
tracts at both exons 3 and 10 but only its exon 10 A8 tract is
mutated in ,85% of colorectal cancers with MSI [19,20]. The
biallelic frameshift mutation causes ACVR2 protein loss, and is
associated with histologically poor grade tumors and significantly
larger volume tumors [20,21]. Restoration of ACVR2 in colon
cancer cells causes growth suppression [22].
Colon cancer cell models highlight the relationship between
defective DNA MMR and TGFBR2 and ACVR2 frameshift
mutations. Both genes commonly have a 21 bp frameshift
mutation with defective MMR. Restoration of wild type (WT)
TGFBR2 and ACVR2 by chromosome transfer reveals growth
suppression in the cells and slower growth in xenografts in nude
mice [22,23]. Interestingly, HCT116+chr3 cells, which have two
mutant hMLH1 and two mutant TGFBR2 alleles plus one WT
hMLH1 and one WT TGFBR2 allele, express ,33% WT TGFBR2
mRNA and ,67% mutant TGFBR2 mRNA (unpublished data).
On the other hand, HCT116+chr2 cells, which have two mutant
hMLH1 and two mutant ACVR2 alleles plus one WT ACVR2 allele,
express ,20% WT ACVR2 mRNA [22], suggesting a slow but
steady mutation of the transferred ACVR2 allele in hMLH1
deficiency.
Determining mutation rates of actual human coding genes in
human MMR deficiency has not been previously performed,
although model systems using noncoding sequences with human
cell and yeast MMR systems have been utilized [24–27]. To test
the hypothesis that TGFBR2 and ACVR2 frameshift mutations are
dependent on the human MMR background, we constructed
EGFP plasmids in which a 21 bp frameshift mutation at coding
microsatellites of TGFBR2 exon 3 and ACVR2 exon 10 was
detected by EGFP expression in human colon cancer cells with
MMR deficiency. With this new cell model, we were able to
calculate a human gene mutation rate in each human MMR-
deficient background, and could directly compare the mutation
rate between TGFBR2 and ACVR2.
Results
Successful cloning and stable transfection of pIREShyg2-
TGFBR2-EGFP and pIREShyg2 ACVR2-EGFP plasmids
The plasmid pIREShyg2-EGFP allows the expression of EGFP
under the control of a constitutive cytomegalovirus promoter,
which is active throughout the cell cycle [25]. We inserted portions
of exon 3 of TGFBR2 or exon 10 of ACVR2 as outlined in Fig. 1
after the translation initiation codon of the EGFP gene, either in-
frame of an EGFP (IF) or +1 bp out of frame of the EGFP (OF) in
pIREShyg2-EGFP. For experimental plasmids, TGFBR2 or
ACVR2 sequences were cloned +1 bp OF in pIREShyg2-EGFP
and thus a 21 bp frameshift mutation at the coding microsatellite
would shift the EGFP gene into the proper reading frame to allow
Figure 1. pIREShyg2-TGFBR2-EGFP and pIREShyg2-ACVR2-EGFP plasmids. Portions of exon 3 of TGFBR2 and exon 10 of ACVR2 sequences
containing coding microsatellites were inserted immediately after the start codon of the EGFP gene, being in frame with EGFP (IF) or +1 bp out of
reading frame with the EGFP (OF) in pIREShyg2-EGFP. Mutation resistant (MR) plasmids were constructed by interrupting the coding microsatellite
sequences (A10 to A2CA2GA2CA in TGFBR2 and A8 to A3GA4 in ACVR2), preventing frameshift mutation. Deletion of 1 bp in OF plasmids, experimental
plasmids, restores the proper reading frame and allows EGFP expression. MR IF and MR OF plasmids were used for positive and negative control for
EGFP expression, respectively.
doi:10.1371/journal.pone.0003463.g001
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were constructed by interrupting the coding microsatellites (A10 to
A2CA2GA2CA in TGFBR2 and A8 to A3GA4 in ACVR2) and
would be resistant to frameshift mutation. The MR TGFBR2 and
MR ACVR2 plasmids were placed OF (+1 bp) and IF to be used as
negative and positive controls for EGFP expression, respectively.
Transient transfections of these plasmids into the hMLH1
2/2
background were performed to verify their EGFP expression in
cells and detected by a fluorescence microscope before stable cell
lines with different MMR deficiency were established. Positive
controls expressed EGFP whereas negative controls did not
express EGFP in the cells.
Subsequently, twenty-four stable cell lines with differing MMR
genetic backgrounds (Table S1) were established with hygromycin
B selection after transfection, as outlined in Table S2. After
selection, colonies from each cell line were initially pooled and
cultured for mutation analysis. After 5 weeks, the proportion of
fluorescent cells within each cell line was measured by flow
cytometry. All eight cell lines containing MR TGFBR2 IF or MR
ACVR2 IF sequence showed fluorescence between 88% and 100%
(median 99.1%), indicating robust selection efficiency of the MR IF
stable cell lines (Fig. 2). In hMLH1
2/2 and hMSH6
2/2 cells
containingTGFBR2OF orACVR2 OF sequences, newly fluorescent
cells were observed ranging between 0.14% and 1.22% (median
0.32%) net fluorescence over counterpart cell lines containing MR
TGFBR2 OF or MR ACVR2 OF sequences. The hMLH1
2/2 cells
with TGFBR2 OF sequence showed the highest net fluorescence
(1.22%) among cell lines with TGFBR2 OF or ACVR2 OF sequences
(Fig. 2). On the other hand, hMSH3
2/2 and MMR proficient
stable cell lines did not show any net fluorescence.
TGFBR2 exon 3 and ACVR2 exon 10 coding microsatellite
mutations are dependent on the MMR background
To determine mutation frequencies of the TGFBR2 and ACVR2
coding microsatellites in cells with different MMR backgrounds
(Table S1), nonfluorescent cells containing either MR TGFBR2
OF, TGFBR2 OF, MR ACVR2 OF or ACVR2 OF were sorted and
exponentially grown for 7 to 35 days. At specific time points (day
7, 14, 21, 28, and/or 35) three cultures of each cell line were
analyzed in parallel for EGFP expression by using flow cytometry
to detect 21 bp frameshift mutations. Three different populations
were identified according to their EGFP fluorescence intensity
(Fig. 3). The population with no fluorescence was named M0, the
population with low fluorescence M1, and the population with
high fluorescence M2. EGFP histograms of MR TGFBR2 OF and
TGFBR2 OF cells in different MMR backgrounds at day 21 are
shown in Fig. 3E, in which hMLH1
2/2 TGFBR2 OF cells showed
2 distinct EGFP cell populations, M1 and M2. M2 cells from
hMLH1
2/2 TGFBR2 OF showed brighter EGFP expression
compared to M1 cells (Fig. S1).
The 21 bp mutation frequency at each time point was
expressed as a fold change using the following formula: (EGFP
positive cells/total live cells from TGFBR2 OF or ACVR2 OF
cells)/(EGFP positive cells/total live cells from MR TGFBR2 OF
or MR ACVR2 OF cells) (Fig. 4). The M2 population accumulated
over time (most dramatically with TGFBR2 and ACVR2 sequences
in hMLH1
2/2 background) whereas the M1 population showed
little change (Fig. 4), indicating that M1 and M2 are distinct
populations. The M1 and M2 populations were plotted separately
for analysis of mutation frequency.
In the M1 population, mutation frequency of the TGFBR2
sequence in hMLH1
2/2 cells was higher than other cell lines and
increased over time (highest at day 35, 21-fold change), although
the increase over time was small when compared to the increase in
the M2 population (Fig. 4A). There was no consistent increase in
the M1 population in other cell lines over time except hMSH3
2/2
TGFBR2 cells that showed a slow increase in mutation frequency
up to day 35 (5-fold change). In the M2 population, the TGFBR2
sequence in the hMLH1
2/2 background demonstrated the highest
mutation frequency (highest at day 21, 240-fold change) over time
Figure 2. EGFP expression of stably transfected HCT116 cell lines (hMLH1
2/2) containing exon 3 of TGFBR2 sequences. (A) MR TGFBR2
IF cells, a postive control, showed 99% EGFP expression. (B) MR TGFBR2 OF cells, a negative control, showed no visible fluorescence. (C) TGFBR2 OF
cells showed 1.22% net fluorescence. Photomicrographs of stable HCT116 cell lines are representative of the other stable cell lines containing TGFBR2
exon 3 or ACVR2 exon 10 sequences. Photomicrographs in top panels were taken with a fluorescence microscope (Zeiss, Germany) and
photomicrographs in bottom panels were taken with a light microscope of the identical area under 406magnification.
doi:10.1371/journal.pone.0003463.g002
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predicted in EGFP histograms (Fig. 3E). Mutation frequency of
the TGFBR2 sequence in the hMSH6
2/2 background also
increased over time and showed the highest mutation frequency
on day 35 (14-fold change), although this frequency is much lower
than TGFBR2 sequence in hMLH1
2/2 cells (Fig. 4B). At day 35,
frameshift mutation of ACVR2 sequence in the hMLH1
2/2
background was 79-fold higher than the negative control whereas
ACVR2 sequence in the hMSH6
2/2 background showed a 4-fold
change in mutation frequency. In all hMSH3
2/2 stable cell lines,
M2 cells were rare events (average 0.009%) at all time points and
there was no significant difference in numbers of the M2
population between MR TGFBR2 or MR ACVR2 OF and
TGFBR2 or ACVR2 OF cells, respectively, as shown in Fig. 3E.
Thus, fold changes in the M2 population were 1 at all time points
for both TGFBR2 and ACVR2 sequences in hMSH3
2/2 cell lines
(Fig. 4B).
The M1 population represents pass-through
heteroduplexes, while the M2 population represents fully
mutant sequences
To confirm that fluorescence from the M1 and M2 populations
was driven by 21 bp frameshift mutation at the coding
microsatellites of TGFBR2 OF and ACVR2 OF, at day 21 after
being plated as nonfluorescent cells, cells from the M1 and/or M2
populations of hMLH1
2/2 TGFBR2 OF or ACVR2 OF cells,
hMSH6
2/2 TGFBR2 OF or ACVR2 OF cells, and hMSH3
2/2
TGFBR2 OF or ACVR2 OF cells were sorted and expanded for
sequencing analysis. DNA from each cell line was amplified by
PCR, sub-cloned into a TA cloning vector and single cell clones
were individually sequenced to assess for frameshift mutation at
the coding microsatellites of TGFBR2 exon 3 and ACVR2 exon 10.
As expected, nearly all DNA clones (86–100%) from the M2
population of all cell lines with hMLH1
2/2 and hMSH6
2/2
revealed 21 bp frameshift mutation (A9 at TGFBR2 and A7 at
ACVR2), indicating fully mutant sequences inducing EGFP
expression (Fig. 5A). Rare A8 sequences were observed in M2
clones from hMSH6
2/2 TGFBR2 OF cells. In particular, all clones
from the M2 population of hMLH1
2/2 TGFBR2 OF cells revealed
frame shift mutations (A9) with no wild type A10 sequence
(Fig. 5A). This observation correlates with the highest mutation
frequency of hMLH1
2/2 TGFBR2 cells over time (Fig. 4B). In
comparison, clones from the M1 population of hMLH1
2/2
TGFBR2 OF and hMLH1
2/2 ACVR2 OF revealed 84 and 69%
of mutant (A9 and A7) microsatellites, respectively, and clones from
the M1 population of hMSH6
2/2 TGFBR2 OF and hMSH6
2/2
ACVR2 OF cells expressed 50 and 53% of mutant (A9 and A7)
microsatellites, respectively (Fig. 5A). A rare A11 sequence was
also observed in M1 clones from hMSH6
2/2 TGFBR2 OF cells. In
the M1 population, clones of hMLH1
2/2 TGFBR2 OF cells
showed a 21 bp frameshift mutation in 84%, corresponding to the
Figure 3. Mutation analysis by flow cytometry. Nonfluorescent cells were sorted and cells were exponentially grown for 7 to 35 days. At specific
time points, cells were harvested, and 200,000 cells were analyzed for EGFP expression (identifying a 21 bp mutation) by flow cytometry. For
example, with hMLH1
2/2 ACVR2 OF cells, region R1, R3, and R2 were set according to (A) cell size, (B) live cells, and (C) fluorescence. Gated R1 and R3
(live cells), and R2 were analyzed on an EGFP histogram (D) and two distinct EGFP populations were plotted. The population displaying no
fluorescence was designated M0, the population with dim EGFP expression was designated M1, and the population with bright EGFP expression was
designated M2. (E) EGFP histograms of MR TGFBR2 OF and TGFBR2 OF cells in different MMR deficient backgrounds at day 21 were shown as
representatives of mutation analysis. Scaling of cell counts in each EGFP histogram is different for each MMR background.
doi:10.1371/journal.pone.0003463.g003
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cell lines over time (Fig. 4A). Only five percent (1/20) of M1 clones
from hMSH3
2/2 TGFBR2 OF cells revealed a mutated microsat-
ellite sequence (A9)( Fig. 5A). The M1 population from hMSH3
2/2
ACVR2 OF cells did not show any frameshift mutation (data not
shown) and thus sub-cloning was not done for sequencing analysis.
As expected, all MR stable cell lines did not show frameshift
mutations at microsatellites with MMR-deficiency. In addition, all
MMR proficient HT29 stable cell lines did not show any frameshift
mutations at microsatellites of TGFBR2 and ACVR2.
To determine the nature of the mutations observed in the M1
population, we analyzed pooled cells as well as single cell clones. In
pooled samples, unlike fully mutant sequences observed in the M2
populations, M1 population sequences often revealed two overlap-
ping sequences, suggestive of heteroduplexes (A9/T10 in TGFBR2
and A7/T8 in ACVR2)( Fig. 5B). Single cell clones revealed the
presence of both WT and 21 bp frameshift mutants (Fig. 5B),
consistent with heteroduplexes that weakly drive EGFP expression.
Overall, our data indicate that hMLH1 deficiency has the highest
susceptibility for frameshift mutation at the coding microsatellites of
TGFBR2 exon 3 and ACVR2 exon 10 of the three different MMR
deficiencies (hMLH1
2/2, hMSH6
2/2 and hMSH3
2/2). In addition,
the coding microsatellite of TGFBR2 exon 3 has a higher
susceptibility to a 1 bp frameshift mutation than that of ACVR2
exon 10 in hMLH1, hMSH6,( a n dhMSH3) deficiencies.
The frameshift mutation rates at the coding
microsatellites of TGFBR2 exon 3 and ACVR2 exon 10 are
dependent on the MMR background
The M2 population (full mutants) was used to calculate the
mutation rates at microsatellites of TGFBR2 exon 3 and ACVR2
exon 10 by the ‘‘method of the mean’’ [28] (Table 1). A single
mutation rate was calculated by taking a weighted average of the
mutation rates at the different time points, the weights of which
were chosen to minimize the variance of the estimate as previously
described [25]. As predicted, the mutation rate at the microsat-
ellite of TGFBR2 in the hMLH1
2/2 background was highest:
5.91610
2461.26610
24. Mutation at the A10 microsatellite of
TGFBR2 is ,3 times more frequent than mutation at the A8
microsatellite of ACVR2 in hMLH1 deficiency (P,0.01). In
addition, mutation at the microsatellite of TGFBR2 is ,4 times
higher than mutation at the microsatellite of ACVR2 in hMSH6
deficiency. Furthermore, mutations at the microsatellites of
Figure 4. Mutation frequencies of TGFBR2 exon 3 and ACVR2 exon 10 are dependent on the MMR background. Nonfluorescent cells
were analyzed for EGFP expression by flow cytometry at 7, 14, 21, 28, and/or 35 days after being sorted and cultured, and EGFP analysis was
performed as described in Fig. 3. Mutation frequency at each time point was expressed as a fold change using the following formula: (EGFP positive
cells/total live cells from TGFBR2 OF or ACVR2 OF cells)/(EGFP positive cells/total live cells from MR TGFBR2 OF or MR ACVR2 OF cells). Overall, the M1
population showed little change in mutation frequency whereas mutation frequency of the M2 population accumulated over time, indicating that
M1 and M2 populations are distinct populations. In the M2 population, note that the hMLH1 deficiency conferred higher mutation frequencies in
both ACVR2 and TGFBR2 sequences compared to hMSH6 and hMSH3 deficiencies and that TGFBR2 sequence showed a higher mutation frequency
than ACVR2 sequence in identical MMR deficiencies. Cell lines showing lower mutation frequencies (less than 25-fold change) were separately plotted
in the right panel using a smaller y-axis scale. Data are means from three independent experiments at each time point.
doi:10.1371/journal.pone.0003463.g004
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deficiency than in hMSH6 deficiency (P,0.01). Mutation rates
from hMSH3
2/2 and MMR-proficient cell lines were not
calculated due to a lack of net fluorescent M2 populations. These
data confirm that hMLH1 deficiency allows a higher susceptibility
for mutation at the coding microsatellites of TGFBR2 exon 3 and
ACVR2 exon 10 than hMSH6 and hMSH3 deficiencies, and that
TGFBR2 exon 3 has a higher susceptibility to mutation at its
coding microsatellite over ACVR2 exon 10 in both hMLH1 and
hMSH6 deficiencies.
Discussion
In this study, we developed an experimental model in which the
actual human coding sequences of TGFBR2 exon 3 and ACVR2
exon 10 were evaluated in real time for 21 bp frameshift
mutations in human cells with differing MMR genetic back-
grounds (hMLH1
2/2, hMSH6
2/2, hMSH3
2/2, and MMR-
proficient). Our aim was to test the hypothesis that the frequency
and rate of targeted genes for frameshift mutation in human MSI
tumors are dependent on the MMR genetic background. 21b p
frameshift mutations in exon 3 of TGFBR2 and exon 10 of ACVR2
are common in MSI tumors, and are thought to help drive the
pathogenesis of colorectal cancers manifesting MSI. Although the
general frequencies of TGFBR2 and ACVR2 mutations are culled
from general colorectal cancer cohorts, there is no experimental
data on mutation rates of these targeted genes and how MMR
deficiency can influence those rates.
In this study, we made several unique observations: (1) the
21 bp frameshift mutations at coding microsatellites within
human TGFBR2 exon 3 and ACVR2 exon 10 sequences were
observed in real time in different human MMR deficient
backgrounds; (2) both coding microsatellites of TGFBR2 and
ACVR2 mutate through heteroduplex formation (M1) before full
mutation (M2); (3) MMR-deficient backgrounds determine the
mutation frequency and rate of the coding microsatellites of
TGFBR2 and ACVR2, for which hMLH1.hMSH6.hMSH3
deficiency; (4) hMSH3
2/2 background does not generate any
significant frameshift mutation in the tested sequences; and (5) the
coding A10 microsatellite of TGFBR2 mutates at a higher rate than
the A8 coding microsatellite of ACVR2 in hMLH1
2/2 and
hMSH6
2/2 backgrounds.
Our experimental model revealed two distinct fluorescent
populations of mutant cells, M1 expressing dim EGFP and M2
expressing bright EGFP (Fig. 3). The M2 population accumulated
over time whereas the M1 population showed little change (Fig. 4).
These observations were similar to a study that observed
frameshift mutation at a noncoding (CA)13 microsatellite in an
hMLH1
2/2 background [25].
We confirmed that EGFP expression from M1 and M2
populations was driven as a result of a 21 bp frameshift mutation
of TGFBR2 OF and ACVR2 OF cells by TA subcloning and DNA
sequencing analysis (Fig. 5). In particular, the M2 clones from
hMLH1
2/2 TGFBR2 OF cells revealed that all clones underwent
21 bp frameshift mutation, indicating that the M2 clones are fully
mutant cells containing a frameshifted A9/T9 microsatellite. The
M2 clones from hMSH6
2/2 TGFBR2 OF, hMLH1
2/2 ACVR2
OF, and hMSH6
2/2 ACVR2 OF cells showed ,10–15% WT
microsatellite sequences that are derived from the M1 cell
population. Clones from M1 populations in hMLH1
2/2 and
Figure 5. Frameshift mutation at coding microsatellites of
TGFBR2 exon 3 and ACVR2 exon 10 in different human MMR
deficient backgrounds. Cells from the M1 and/or M2 populations of
hMLH1
2/2 TGFBR2 OF or ACVR2 OF cells, hMSH6
2/2 TGFBR2 OF or
ACVR2 OF cells, and hMSH3
2/2 TGFBR2 OF cells were sorted and
cultured. DNA from each cell line was amplified by PCR, sub-cloned and
all single cell clones were individually sequenced to assess for
frameshift mutation of the coding microsatellites of TGFBR2 exon 3
and ACVR2 exon 10. Sequence analysis of DNA clones from hMLH1 and
hMSH6 deficiencies revealed mostly 1 bp deletion at microsatellites (A9
for TGFBR2 or A7 for ACVR2), shifting the EGFP gene into the reading
frame and leading to its expression (A). Note that M2 clones from
hMLH1
2/2 TGFBR2 OF cells revealed 100% A9/T9 microsatellite
sequences, termed a ‘‘full mutant’’ whereas M1 clones revealed a
mixture of A10/T10 and A9/T9 microsatellite sequences, which suggests
the presence of an A10/T9 heteroduplex, termed an ‘‘intermediate
mutant’’ (B).
doi:10.1371/journal.pone.0003463.g005
Table 1. Calculated mutation rates at coding microsatellites
of TGFBR2 exon3 and ACVR2 exon 10 in cells with MMR
deficiency.
MMR Background Gene Microsatellite Rate for mutation
hMLH1
2/2 TGFBR2 A10RA9 5.91610
2461.26610
24 *
hMLH1
2/2 ACVR2 A8RA7 2.18610
2460.22610
24 {
hMSH6
2/2 TGFBR2 A10RA9 0.54610
2460.18610
24
hMSH6
2/2 ACVR2 A8RA7 0.14610
2460.04610
24
Data from the M2 cell population from each time point between day 14 and
day 35 were used for mutation rate analysis. Single mutation rates were
calculated by combining and averaging time-specific mutation rates. Rates are
expressed as mutations at microsatellite sequence per cell per generation. Data
shown are mean6SEM. *P,0.01 comparing hMLH1
2/2 TGFBR2 with each of
hMLH1
2/2 ACVR2, hMSH6
2/2 TGFBR2,a n dhMSH6
2/2 ACVR2.
{ P,0.01
comparing hMLH1
2/2 ACVR2 with each of hMSH6
2/2 TGFBR2, and hMSH6
2/2
ACVR2.
doi:10.1371/journal.pone.0003463.t001
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2/2 backgrounds revealed the coexistence of mutated
(65614%, A9 for TGFBR2 and A7 for ACVR2) and WT (35614%,
A10 and A8) microsatellite sequences, indicating the existence of
intermediate mutant cells containing A8/T7 or A10/T9 heterodu-
plexes within the M1 population transferring into full mutant cells
as previously observed [25]. Relative to the M2 population, the
M1 population increased initially but reached a steady state as a
constant supply of actively mutating cells transitioned into the M2
population. Although ,5% of cells in hMSH3
2/2 TGFBR2
revealed mutated microsatellite sequence (A9) in the M1
population, none transitioned into the M2 population. This is
likely due to repair by hMutSa at the IDL, for which hMutSb is
not needed for repair.
As we hypothesized, the mutational frequencies and rates of
TGFBR2 exon 3 and ACVR2 exon 10 microsatellites are dependent
on the MMR deficient background with hMLH1
2/2.hMSH6
2/2
.hMSH3
2/2.A sTGFBR2 and ACVR2 mutations may drive the
pathogenesis of colorectal cancers, our human data is consistent
with the virulence of tumor formation in Lynch syndrome.
Patients with germline mutation in hMLH1 may present with
cancer at younger ages compared to those with a hMSH6 germline
mutation [29]. Data on mutation rates for TGFBR2 exon 3 and
ACVR2 exon 10 (Table 1) showed similar results. hMLH1
2/2
TGFBR2 showed the highest mutation rate at its coding
microsatellite sequence (5.91610
24). This mutation rate is similar
to that calculated for noncoding (CA)13 microsatellites in
hMLH1
2/2 cells [25], suggesting that this coding A10 and the
noncoding (CA)13 microsatellites are equally vulnerable to hMLH1
deficiency. The mutation rate for TGFBR2 was 3 fold higher than
that for ACVR2 in both hMLH1 (5.91610
24) and hMSH6
(0.54610
24) deficiencies. The rapid rate for TGFBR2 mutation
with MMR deficiency might be due partly to TGFBR2’s longer
polyadenine tract compared to ACVR2, as longer microsatellite
tracts mutate more frequently in MMR deficiency [7]. In the case
of ACVR2 exon 10, even though the mutation rate is slower than
TGFBR2 exon 3, ultimately fully mutant clones accumulate. The
rapid rate for TGFBR2 exon 3 mutation is probably most reflective
in the M1 population, as there is a rapid heteroduplex formation
particularly in hMLH1 deficiency, followed by full mutation. In
ACVR2 exon 10, heteroduplex formation is relatively slower. With
both TGFBR2 and ACVR2 constructs, heteroduplex formation and
subsequent full mutation are slower in the hMSH6
2/2 background
compared to hMLH1
2/2 background. It has been shown that
MSH6 and MSH3 are redundant in regard to frameshift
mutagenesis in a yeast model [30], which supports our finding
that hMSH6 and hMSH3 defects have much lower frameshift
mutation rates than the hMLH1 defect that completely eliminates
MMR. Lower frameshift mutation rate in hMSH6 deficiency
would logically predict a lower penetrance in Lynch syndrome for
which no germline hMSH3 mutation has been reported.
In summary, we established and utilized a cell model in which
actual human coding microsatellite sequences of TGFBR2 exon 3
and ACVR2 exon 10 were evaluated in real time for frameshift
mutation in different human MMR backgrounds. hMLH1
deficiency confers a significantly higher mutation rate at the
coding microsatellites of TGFBR2 and ACVR2 compared to
hMSH6 and hMSH3 deficiencies. In addition, TGFBR2 mutates
at a higher rate than ACVR2 in both hMLH1 and hMSH6
deficiencies. These bona-fide human genes targeted for mutation
in MMR deficiency mutate at differing rates, and lose expression
of their encoded proteins in colonic neoplastic cells. Understand-
ing these targeted genes in MMR deficiency has implications in
understanding the pathogenesis of MSI colorectal tumors.
Materials and Methods
Cloning of pIREShyg2-TGFBR2-EGFP and pIREShyg2-
ACVR2-EGFP plasmids
Plasmid pIREShyg2-EGFP was a kind gift from C. Richard
Boland, MD (Baylor Univ. Med Center, Dallas, TX). Details of
cloning of pIREShyg2-EGFP were previously described [24].
Portions of exon 3 of TGFBR2 and exon 10 of AVCR2 (shown in
Fig. 1) were amplified by PCR from the MMR proficient human
colon carcinoma cell line FET (kind gift of Michael Brattain, Ph.D.
Roswell Park Cancer Inst; Buffalo, NY). New PmeI and AscI sites
were created in the 59 and 39 ends of those TGFBR2 and ACVR2
sequences by PCR, respectively (primers: 59-
GCGTCGTTTAAACCTGCTTCTCCAAAGTGCATTATG-
39 and 59-AAGGCGCGCCAAGAAAGTCTCACCAGGCTT-39
for TGFBR2 and 59- AGCTTTGTTTAAACGACCTGTAGAT-
GAATACATGT-39 and 59-AAGGCGCGCCAAACAGGCCT
CTTTTTTTTATG-39 for ACVR2). The PCR products and
pIREShyg2-EGFP were digested with PmeI and AscI (New
England Biolabs, Ipswich, MA) and the digested PCR products
were cloned into PmeI–AscI sites of pIREShyg2-EGFP to generate
pIREShyg2-TGFBR2-EGFP and pIREShyg2-ACVR2-EGFP
plasmids (Fig. 1). Experimental plasmids were constructed in
which the TGFBR2 and ACVR2 sequences were cloned +1b pO F
in pIREShyg2-EGFP immediately after the translation initiation
codon of the EGFP gene, and thus frameshift mutation of 21b p
would allow expression of EGFP (Fig. 1). As negative control
plasmids for EGFP expression, mutation resistant (MR) counter-
part plasmids (+1 bp OF plasmids) were constructed by changing
1 or 3 nucleotide sequences (A10 to A2CA2GA2CA in TGFBR2
and A8 to A3GA4 in ACVR2) within microsatellites using a
Quickchange II site-directed mutagenesis kit (Stratagene, La Jolla,
CA), preventing any frameshift mutation (Fig. 1). MR IF plasmids
containing portions of TGFBR2 or ACVR2 were constructed as
positive controls for EGFP expression (Fig. 1). The ligation
products were transformed into DH5a cells. Positive colonies were
screened, and the correct sequences of TGFBR2 and ACVR2 were
confirmed by sequencing in an ABI 3700 analyzer.
Cell lines, transfection, and selection
The human colon cancer cell lines, HT29 (MMR proficient),
HCT116 (hMLH1
2/2 and hMSH3
2/2), and DLD-1 (hMSH6
2/2)
were obtained from American Type Culture Collection (Rockville,
MD) and maintained in either Dulbeeco’s modified Eagle’s medium
(DMEM, Invtrogen Corp, Carlsbad, CA, for HT29 cells) or Iscove’s
modified Dulbeeco’s medium (IMDM, Invitrogen Corp, for
HCT116 and DLD-1 cells) with 10% fetal bovine serum (FBS)
and penicillin (100 U/ml)/streptomycin (100 mg/ml) (P/S, Invitro-
gen Corp) as supplements. The HCT116 cell line containing
transferred chromosome 3 (HCT116+chr3, hMLH1 restored but
hMSH3
2/2) was developed as previously described [6] and
maintained in IMDM containing 10% FBS, P/S, and 400 mg/ml
ofG418sulfate(CellGro,Manassas,VA).Cellsweretransfected with
various pIREShyg2-TGFBR2-EGFP and pIREShyg2-ACVR2-
EGFP plasmids by using Nucleofector kit V and L (Amaxa,
Cologne, Germany), following the manufacturer’s instructions.
Selection with hygromycin B (Invitrogen Corp) was started at
24 hr after nucleofection to generate stable cell lines. After selection,
colonies from each cell line were initially pooled and cultured for
mutation analysis. All stablecell lines were confirmed by sequencing.
Analysis of mutant cells by flow cytometry
Five thousand nonfluorescent cells expressing MR TGFBR2 OF,
TGFBR2 OF, MR ACVR2 OF, or ACVR2 OF were sorted into 24-
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Dickinson Immunocytometry Systems (BDIS), San Jose, CA).
During a 7 to 35 day analysis period, cultures were expanded as
required to keep cells in exponential growth. Cells were
trypsinized, washed in PBS, and resuspended in a total volume
of 200 ml of PBS/0.5 mg/ml of propidium iodide (PI) and 3%
BSA. Cell suspensions were analyzed on a FACSCalibur with
CELLQUEST acquisition and analysis software (BDIS, CA). At
specified time points, three cultures were analyzed in parallel. To
identify EGFP-positive cells, region 1 (R1) was set in the forward/
side scatter and region 3 (R3) was set in the forward/PI scatter,
and then R1 and R3 were gated by live cells. Region 2 (R2) was set
in the fluorescence 1 (FL1, green)/fluorescence 2 (FL2, red)
scatter. Cells from the gated R1, R3, and R2 were plotted further
on a fluorescence intensity histogram, and three populations were
separated. The population displaying no fluorescence was named
M0, the population with low fluorescence intensity, M1, and the
one with high fluorescence intensity, M2. The counts of M1 and
M2 cells were expressed as percentages of R3 (total live cell
number).
PCR and DNA sequencing
Total cellular DNA from stable cell lines and M1 and M2 cell
populations were PCR-amplified by specific primers (59-GCG
TCGTTTAAACCTGCTTCTCCAAAGTGCATTATG-39 and
59-TGCCGTCGTCCTTGAAGAAGA-39 for exon 3 of TGFBR2
and 59- GATCCGCCACCATGTTTAAACGAC-39 and 59-
GCTGTTGTAGTTGTACTCCAGCTTG-39 for exon 10 of
ACVR2) in a reaction containing the primers, buffer, DNA template,
deoxynucleotides, and Pfu Ultra high fidelity DNA polymerase
(Stratagene). The PCR products were used for DNA sequencing to
identify stable cell lines and frameshift mutations at coding
microsatellites. In addition, we subcloned PCR-amplified TGFBR2
and ACVR2 DNA fragments from M1 and M2 cell populations
utilizing a TA cloning vector (Invitrogen Corp) as per the
manufacturer’s protocol. DNA clones were then individually
sequenced to determine the prevalence of mutated and WT
TGFBR2 and ACVR2 sequences.
Determination of 21 bp frameshift mutation rates of
TGFBR2 exon 3 and ACVR2 exon 10 in human cells
The mutation rate was defined as the probability of a cell
undergoing a mutation in its lifetime and expressed per cell per
generation. We used a ‘‘method of the mean’’ developed by Luria
and Delbruck [28] to estimate mutation rate. The ‘‘method of the
mean’’ is moment-based, whereby the mutation rate is estimated
as a function of the sample mean of the number of mutants. The
formula used in the computation is r ˆ=mN ln(mNC), where r ˆ is the
mean number of mutants in a culture, C is the number of parallel
cultures, m is the mutation rate, and N is the number of cells at risk
of undergoing a mutation, which Luria–Delbruck assumed to be
equal to the final number of cells in a culture. Three parallel
cultures were used, and r ˆ was estimated as the mean of the number
of mutants across the three cultures. The total number of cells N
was based on averaging across cultures. The formula listed above
was used to calculate mutation rates of the M2 cell population (full
mutants) using data from flow cytometry analysis at each time
point between day 14 and day 35. Single mutation rates were then
calculated by combining and averaging time-specific mutation
rates to minimize the variance of the estimate as previously
described [25]. Data were expressed as mean6the standard errors
of mean (SEM).
Statistical analysis
Mutation rates of cell lines were compared by T-test or one-way
ANOVA.
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Table S1 MMR genetic background of cell lines.
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exon 10 of ACVR2.
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